Objective:
The article examines the objective, findings, and clinical context described in FDA Accepts Vamikibart BLA for Uveitic Macular Edema.
Approach:
- Trials: MEERKAT and SANDCAT were identically designed phase 3 trials enrolling 245 and 256 adults with UME associated with noninfectious uveitis. Participants were randomized to intravitreal vamikibart 0.25 mg, vamikibart 1 mg, or sham.
- Assessment: The primary endpoint was a gain of at least 15 ETDRS letters at week 16. Efficacy and safety were followed through week 52; rescue and as-needed treatment were permitted under specified criteria.
Key Findings:
- Week 16 primary endpoint results differed between trials. In MEERKAT, response rates were 26.1% with 0.25 mg and 43.2% with 1 mg versus 6.3% with sham; both comparisons were statistically significant.
- In SANDCAT, week 16 response rates were 34.0%, 21.8%, and 13.3%, respectively. The 1-mg comparison was not statistically significant; the 0.25-mg result was nominally significant under the trial’s testing hierarchy.
- Visual acuity and central subfield thickness improvements appeared as early as day 8 and were generally maintained through week 52. At week 52, mean central subfield thickness reductions exceeded sham in both trials.
- More than half of sham-treated patients required rescue treatment, compared with approximately 20% of vamikibart-treated patients. Among patients eligible for as-needed dosing, approximately 30% required additional injections; about 85% of those received one a…
- Through week 52, reported rates of serious ocular adverse events and intraocular inflammation were relatively low. No ocular occlusive retinal vasculitis cases or new safety signals during the as-needed phase were reported.
- The FDA accepted Genentech’s biologics license application. The company said an FDA decision is expected by July 2027.
Interpretation:
The reported 52-week findings showed generally sustained visual and anatomic improvements, but the trials differed in their week 16 primary endpoint results. Vamikibart remains investigational.
Limitations:
- The primary endpoint results differed between MEERKAT and SANDCAT.
- Week 52 responder-rate comparisons in SANDCAT were not nominally statistically significant.
- The context provides no detailed numerical safety rates or full statistical analyses for the 52-week outcomes.
Conclusion:
Vamikibart is an investigational IL-6-inhibiting monoclonal antibody being evaluated as a nonsteroid treatment for UME. The FDA has accepted its application; approval has not been reported.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







